Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Drug Information » New Medical Therapies™

Weight Loss

May 26, 2014

Novo Nordisk has reported results of a phase IIIa trial of liraglutide for weight loss. The randomized, double-blind, placebo-controlled, multinational trial enrolled 3,731 non-diabetic obese subjects and non-diabetic overweight subjects with comorbidities. Subjects were randomized to treatment with liraglutide 3mg or placebo in combination with diet and exercise for 56 weeks or 160 weeks of treatment based on pre-diabetes status at screening. The proportion of adults achieving weight loss of 5% or more of their baseline body weight was 64% for liraglutide 3mg treatment compared to 27% for placebo (P<0.0001). In addition, 33% of adults treated with liraglutide 3mg achieved weight loss greater than 10% of their baseline body weight compared to 10% for placebo (P<0.0001). Treatment with liraglutide 3mg significantly reduced waist circumference by -8.19 cm, compared to -3.94 cm with placebo (P<0.0001). Novo Nordisk has submitted an NDA to the FDA and an MAA to the EMA for liraglutide 3mg for chronic weight management in adults.

October 1, 2012

Zafgen issued results from a phase Ib trial of beloranib for the reduction of body fat, rapid weight loss and improvements in cardiovascular disease risk in obese females. This randomized, double-blind, placebo-controlled study enrolled obese women with a mean (SEM) age of 45.7 years, body weight of 104.9kg and BMI of 39.5kg/m2. Subjects were randomized into three arms and received beloranib 3.0mg or 6.0mg, or placebo, twice weekly for four weeks. Patients were allowed to eat normally and were not counseled to change their exercise habits. After four weeks, subjects on 3.0mg beloranib lost an average of 4.7kg from baseline (p=0.0008), 6.0mg beloranib lost 6.7kg (p=0.0013) and placebo-dosed subjects gained an average of 0.2kg. Body composition measurements were consistent with reduced adipose tissue mass. Despite the fact that they lost weight, hunger tended to be reduced (-28% with 3.0mg, -52% with 6.0mg, -2% with placebo). Blood pressure (BP) and glucose did not change with treatment. The drug was well tolerated. The most frequent adverse events were mild diarrhea, nausea, headache, dizziness, infusion site injury and sleep disturbance. Based on these data, Zafgen will expand its clinical development program to include more subjects.

December 12, 2011

Acacia Pharma issued results from a phase IIa trial of APD209 for cancer cachexia. The trial enrolled 13 subjects with an average weight loss of 11.4% in the previous six months. The subjects received APD209 for eight weeks. The primary efficacy endpoint was major response, defined as an increase in quadriceps muscle size of at least 4% and/or an increase of at least 10% in quadriceps strength. Seven subjects completed the eight week course of treatment, with six achieving a major response. Among the responders, the average increase in quadriceps volume was 6% and quadriceps strength rose on average 16%. Hand grip strength increased on average 17%. Physical activity was also markedly improved in three subjects. In two of these subjects the average daily step count more than doubled between the start and end of treatment. Side effects related to APD209 were generally mild.